Pyrilutamide
Pyrilutamide (KX-826) – a topical androgen-receptor antagonist developed by Kintor for androgenetic alopecia (and acne). INVESTIGATIONAL compound: in phase 2/3 trials (China/US), not approved anywhere, peer-reviewed efficacy data still sparse.
Related comparisons
Clascoterone vs Pyrilutamide vs RU58841WHAT IS PYRILUTAMIDE?
Detailed overview
Pyrilutamide (development code KX-826, Kintor Pharmaceutical) is a TOPICAL androgen-receptor (AR) antagonist being developed for androgenetic alopecia (and acne). It acts on a principle similar to clascoterone: in the dermal papilla cells of the hair follicle it competitively blocks the binding of dihydrotestosterone (DHT) to the androgen receptor, thereby in principle slowing androgen-driven follicular miniaturization – LOCALLY, aiming for low systemic absorption. IMPORTANT: this is an INVESTIGATIONAL compound, currently in phase 2/3 clinical trials (e.g. NCT05218642 US phase 2 male AGA; NCT06126965 phase 3 male AGA; Chinese male and female trials), and it is NOT REGISTERED ANYWHERE. Peer-reviewed, published efficacy endpoints are still lacking – the data come predominantly from trial registries and company announcements. For this reason the card focuses on the mechanism and the investigational status, not on a proven routine treatment.
Development code
KX-826 (Kintor Pharmaceutical)
Status
INVESTIGATIONAL – phase 2/3 (AGA); not approved anywhere
Mechanism of action
Topical androgen-receptor antagonist (local anti-DHT)
Form studied
Topical solution (e.g. 0.5% / 1.0%, 1-2x daily)
Evidence
Early/mid-phase; published efficacy still lacking
Data console
Lab data
Research indications
Investigated uses and mechanisms
Clinical trial (registry)
KX-826 (pyrilutamide) topical solution in male androgenetic alopecia – phase 2 trial (US)
Clinical trial (registry)
KX-826 (pyrilutamide) phase 3 trial in adult male AGA patients
Mucosal regeneration
Epithelial renewal and tight-junction restoration.
Safety
Side effects, stop signs, contraindications
Side effects · 3
- Local scalp reactions: in the trials the most common are mild application-site erythema, itching, flaking or dryness; usually mild and transient.
- Limited long-term safety data: as the compound is INVESTIGATIONAL (phase 2/3), the long-term safety profile is not yet complete; peer-reviewed published data are sparse.
- Systemic antiandrogen effect minimized by design: the intended advantage is LOCAL action (low systemic absorption), but the full human safety picture awaits ongoing trials.
Contraindications · 3
- Not an approved drug, investigational: routine use outside a clinical trial is not advised – there is no approved therapeutic indication.
- Pregnancy and childbearing potential without precautions: as an androgen-receptor antagonist it may pose a theoretical risk to male fetal development; avoid in pregnancy.
- Broken, inflamed scalp; known hypersensitivity to the active or the vehicle.
Related Hair & Skin
Same therapeutic category
Studies
Related research and clinical findings
KX-826 (pyrilutamide) topical solution in male androgenetic alopecia – phase 2 trial (US)
Kintor Pharmaceutical
KX-826 (pyrilutamide) phase 3 trial in adult male AGA patients
Kintor Pharmaceutical
Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies
Maheld J, et al.
Telegram
Have a question about Pyrilutamide?
Educational hair and skin info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation. Talk to a dermatologist!
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.